Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol HIV franchises

Executive Summary

Sales of nucleoside analogue Videx fell 27% to $19 mil. in the U.S. during the quarter as a "result of our repositioning Videx to be used in different therapy," Bristol Oncology & Immunology President Richard Winningham said. "Historically, Videx usage occurred quite a bit in combination with hydroxyurea. Beginning mid-to-late last year, we began to encourage physicians not to use Videx in combination with hydroxyurea and are positioning it with other regimens." Videx labeling was changed in October to warn of two fatalities in patients receiving Videx and hydroxyurea in ACTG 5025. Bristol received a warning letter from FDA for allegedly promoting the Videx/hydroxyurea combination despite the ACTG data (1"The Pink Sheet" Nov. 8, 1999, p. 29)

You may also be interested in...

Bristol Videx Once-Daily Dosing Restricted After Unfavorable Trial Results

Labeling for Bristol-Myers Squibb's Videx (didanosine) has been revised to recommend against once-daily dosing for most patients following negative findings from a clinical trial using the new 200 mg formulation of the drug.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts